Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.

Wei T, Tu W, Zhao B, Lan Y, Bao J, Dai Z.

Sci Rep. 2014 Feb 5;4:3982. doi: 10.1038/srep03982.

PMID:
24496270
[PubMed - in process]
Free PMC Article
2.

A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.

Kankanala J, Latham AM, Johnson AP, Homer-Vanniasinkam S, Fishwick CW, Ponnambalam S.

Br J Pharmacol. 2012 May;166(2):737-48. doi: 10.1111/j.1476-5381.2011.01801.x.

PMID:
22141913
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.

Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.

Clin Cancer Res. 2006 Mar 1;12(5):1630-8.

PMID:
16533791
[PubMed - indexed for MEDLINE]
Free Article
4.

Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Miettinen M, Rikala MS, Rys J, Lasota J, Wang ZF.

Am J Surg Pathol. 2012 Apr;36(4):629-39. doi: 10.1097/PAS.0b013e318243555b.

PMID:
22314185
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.

Langenkamp E, Zwiers PJ, Moorlag HE, Leenders WP, St Croix B, Molema G.

Anticancer Drugs. 2012 Feb;23(2):161-72. doi: 10.1097/CAD.0b013e32834dc279.

PMID:
22075979
[PubMed - indexed for MEDLINE]
6.

Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.

Arao T, Matsumoto K, Furuta K, Kudo K, Kaneda H, Nagai T, Sakai K, Fujita Y, Tamura D, Aomatsu K, Koizumi F, Nishio K.

Anticancer Res. 2011 Sep;31(9):2787-96.

PMID:
21868521
[PubMed - indexed for MEDLINE]
7.

Microbubble-conjugated vascular endothelial growth factor receptor 2 binding peptide.

Nunn A, Pochon S, Tardy I, Tranquart F, Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Feb 14 [updated 2012 Jul 11].

PMID:
22787696
[PubMed]
Books & Documents
8.

VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability.

Gorbunova EE, Gavrilovskaya IN, Pepini T, Mackow ER.

J Virol. 2011 Mar;85(5):2296-303. doi: 10.1128/JVI.02319-10. Epub 2010 Dec 22.

PMID:
21177802
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells.

Latham AM, Bruns AF, Kankanala J, Johnson AP, Fishwick CW, Homer-Vanniasinkam S, Ponnambalam S.

Br J Pharmacol. 2012 Jan;165(1):245-59. doi: 10.1111/j.1476-5381.2011.01545.x.

PMID:
21699503
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B.

Br J Cancer. 2011 Mar 29;104(7):1144-50. doi: 10.1038/bjc.2011.72. Epub 2011 Mar 8.

PMID:
21386843
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R.

Br J Cancer. 2004 Oct 4;91(7):1391-8.

PMID:
15328520
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells.

Gomes E, Papa L, Hao T, Rockwell P.

Mol Cell Biochem. 2007 Nov;305(1-2):179-90. Epub 2007 Jul 24.

PMID:
17646929
[PubMed - indexed for MEDLINE]
13.

Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2.

Kuczynski EA, Viloria-Petit AM, Coomber BL.

Cancer. 2011 Dec 15;117(24):5601-11. doi: 10.1002/cncr.26247. Epub 2011 Jun 20.

PMID:
21692070
[PubMed - indexed for MEDLINE]
Free Article
14.

HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.

Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, Peters KG.

J Biol Chem. 1999 Dec 31;274(53):38183-8.

PMID:
10608891
[PubMed - indexed for MEDLINE]
Free Article
15.

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.

Nieminen T, Toivanen PI, Rintanen N, Heikura T, Jauhiainen S, Airenne KJ, Alitalo K, Marjomäki V, Ylä-Herttuala S.

Biochim Biophys Acta. 2014 Jan;1840(1):454-63. doi: 10.1016/j.bbagen.2013.10.005. Epub 2013 Oct 8.

PMID:
24112971
[PubMed - indexed for MEDLINE]
16.
17.

Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells.

Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC, Ponnambalam S.

Traffic. 2006 Sep;7(9):1270-82.

PMID:
17004325
[PubMed - indexed for MEDLINE]
18.

VEGFR2 signalling contributes to increased endothelial susceptibility to TNF-α under chronic non-uniform shear stress.

Urschel K, Garlichs CD, Daniel WG, Cicha I.

Atherosclerosis. 2011 Dec;219(2):499-509. doi: 10.1016/j.atherosclerosis.2011.09.045. Epub 2011 Oct 4.

PMID:
22019447
[PubMed - indexed for MEDLINE]
19.

The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling.

Jopling HM, Howell GJ, Gamper N, Ponnambalam S.

Biochem Biophys Res Commun. 2011 Jul 1;410(2):170-6. doi: 10.1016/j.bbrc.2011.04.093. Epub 2011 Apr 24.

PMID:
21539813
[PubMed - indexed for MEDLINE]
20.

Microbubble-conjugated vascular endothelial growth factor receptor 2 monoclonal antibody.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Nov 05 [updated 2007 Dec 12].

PMID:
20641945
[PubMed]
Books & Documents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk